---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-001098"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:50:24.095563+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics terminates TRA, adopts governance changes reducing Class B voting to 1 vote

## Summary
- Terminated Tax Receivable Agreement with InCube Labs; no payments or early termination fees required.
- Amended charter reduces Class B common stock voting power from 10 to 1 vote per share.
- Eliminated stockholder written consent, classified board; added supermajority vote to amend bylaws.
- Changes approved by majority holder written consent on Nov 24, 2025; effective Dec 31, 2025.

## SEC filing metadata
- accession: 0001193125-26-001098
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.02, 3.03, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/0001193125-26-001098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/d848686d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-001098
- JSON: https://secwatch.observer/filing/0001193125-26-001098.json
- Plain text: https://secwatch.observer/filing/0001193125-26-001098.txt

## Source-grounded claims
- claim_id: 7e2739e4298fcc092af7414332ddb0b874c77575
  claim: Rani Therapeutics Holdings, Inc.: Filed Restated Charter which reduces Class B voting power from 10 to 1 vote per share, eliminates stockholder ability to act by written consent, opts into Section 203 DGCL, and includes other protective provisions (effective 2025-12-31).
  evidence_excerpt: In connection with the governance changes contemplated by the Purchase Agreement, on December 31, 2025, the Company filed the Restated Charter with the Secretary of State of the State of Delaware, which became effective upon such filing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/0001193125-26-001098-index.htm
- claim_id: caa11ccfabbbf053ebd8703bc5a53134fe906900
  claim: Rani Therapeutics Holdings, Inc.: Adopted Amended and Restated Bylaws to reflect conforming changes resulting from the adoption of the Restated Charter (effective 2025-12-31).
  evidence_excerpt: In connection with the adoption of the Restated Charter, on December 31, 2025, the Company also adopted Amended and Restated Bylaws (the “Bylaws”), which became effective on such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/0001193125-26-001098-index.htm
- claim_id: 6aa0ce0c60aa9c55f982eeea3c9cd64827f468a0
  claim: Rani Therapeutics Holdings, Inc. terminated TRA Termination Agreement with InCube Labs, LLC (effective 2025-12-31).
  evidence_excerpt: the Company entered into a Tax Receivable Agreement Termination and Release Agreement (the “TRA Termination Agreement”) by and between the Company and InCube Labs, LLC (acting on behalf of all the TRA Parties (as defined therein)), pursuant to which the parties agreed to terminate that certain Tax Receivable Agreement, dated August 3, 2021 (the “TRA”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000119312526001098/0001193125-26-001098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.